Skip to main content

Published locations for ELIXA trial: No cardiovascular risk with GLP-1 receptor agonist lixisenatide

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. ELIXA trial: No cardiovascular risk with GLP-1 receptor agonist lixisenatide

User login

  • Reset your password
  • /content/elixa-trial-no-cardiovascular-risk-glp-1-receptor-agonist-lixisenatide
  • /familypracticenews/article/100312/diabetes/elixa-trial-no-cardiovascular-risk-glp-1-receptor-agonist
  • /fedprac/article/100312/diabetes/elixa-trial-no-cardiovascular-risk-glp-1-receptor-agonist
  • /ehospitalistnews/article/100312/diabetes/elixa-trial-no-cardiovascular-risk-glp-1-receptor-agonist
  • /internalmedicinenews/article/100312/diabetes/elixa-trial-no-cardiovascular-risk-glp-1-receptor
  • /clinicalendocrinologynews/article/100312/diabetes/elixa-trial-no-cardiovascular-risk-glp-1-receptor
  • /diabeteshub/article/100312/diabetes/elixa-trial-no-cardiovascular-risk-glp-1-receptor-agonist
  • /ecardiologynews/article/100312/diabetes/elixa-trial-no-cardiovascular-risk-glp-1-receptor-agonist
  • /cardiology/article/100312/diabetes/elixa-trial-no-cardiovascular-risk-glp-1-receptor-agonist
  • /endocrinology/article/100312/diabetes/elixa-trial-no-cardiovascular-risk-glp-1-receptor-agonist
  • /internalmedicine/article/100312/diabetes/elixa-trial-no-cardiovascular-risk-glp-1-receptor-agonist
  • /familymedicine/article/100312/diabetes/elixa-trial-no-cardiovascular-risk-glp-1-receptor-agonist
  • /type-2-diabetes-icymi/article/100312/diabetes/elixa-trial-no-cardiovascular-risk-glp-1-receptor